Novartis Urges FDA to Flag Common Misconceptions About Biosimilars

Drug Industry Daily
A A
Piggybacking on a petition from Pfizer, Novartis called on the FDA to debunk common myths about biosimilars and better educate consumers about their safety and efficacy.

To View This Article:

Login

Subscribe To Drug Industry Daily